AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Research Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer

Hongmei Liu1,2,§, Ding Ma3,§, Jinpeng Chen4,§, Li Ye2, Yiping Li5, Yuexia Xie2, Xue Zhao2, Hanbing Zou2, Xiaojing Chen2, Jun Pu1, Peifeng Liu1,2( )
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
Central Laboratory, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Department of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200127, China
Thyroid Breast Surgery, Nantong First People’s Hospital, Nantong 226001, China
Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

§ Hongmei Liu, Ding Ma, and Jinpeng Chen contributed equally to this work.

Show Author Information

Graphical Abstract

In this research, a targeted nanoplatform based on boronic acid modified ε-polylysine was developed to reverse multidrug resistance in adriamycin (ADR) resistant breast cancer. The nanoplatform, co-delivery of P-glycoprotein (P-gp) siRNA, Bcl-2 siRNA, and doxorubicin, showed a robust suppressing efficiency of ADR resistant breast cancer in vitro and in vivo.

Abstract

Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer patients receiving traditional chemotherapeutics or novel targeted drugs. Here, we developed a targeted nanoplatform based on biodegradable boronic acid modified ε-polylysine to co-deliver P-gp siRNA, Bcl-2 siRNA, and doxorubicin for overcoming the challenge. The targeted nanoplatform showed a robust suppressing efficiency for the invasion, proliferation, and colony formation of adriamycin (ADR) resistant breast cancer cell line (MCF-7/ADR) cells in vitro. The ATP responsiveness of the nanoplatform was also proved in the research. In thein vivo antitumor experiment, the targeted nanoplatform showed a significant inhibition of tumor growth with good biocompatibility. The goal of this study is to develop a novel and facile strategy to prepare a highly efficient and safe gene and drug delivery system for MDR breast cancer based on biocompatible ε-polylysine polymers.

Keywords

multi-drug resistance (MDR)breast canceradenosine triphosphate (ATP) responsivenessε-polylysine

Electronic Supplementary Material

Download File(s)
12274_2022_4254_MOESM1_ESM.pdf (628.2 KB)

References

1

DeSantis, C.; Siegel, R.; Bandi, P.; Jemal, A. Breast cancer statistics, 2011. CA Cancer J. Clin. 2011, 61, 409–418.
Crossref Google Scholar
2

Maughan, K. L.; Lutterbie, M. A.; Ham, P. S. Treatment of breast cancer. Am. Fam. Physician 2010, 81, 1339–1346.
Google Scholar
3

Wang, H.; Mao, X. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des. Devel. Ther. 2020, 14, 2423–2433.
Crossref Google Scholar
4

Fisusi, F. A.; Akala, E. O. Drug combinations in breast cancer therapy. Pharm. Nanotechnol. 2019, 7, 3–23.
Crossref Google Scholar
5

Vaidya, J. S.; Massarut, S.; Vaidya, H. J.; Alexander, E. C.; Richards, T.; Caris, J. A.; Sirohi, B.; Tobias, J. S. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ 2018, 360, j5913.
Google Scholar
6

Krug, D.; Loibl, S. Neoadjuvant chemotherapy for early breast cancer. Lancet Oncol. 2018, 19, e129.
Crossref Google Scholar
7

Cazzaniga, M. E.; Dionisio, M. R.; Riva, F. Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett. 2017, 400, 252–258.
Crossref Google Scholar
8

Cazzaniga, M. E.; Pinotti, G.; Montagna, E.; Amoroso, D.; Berardi, R.; Butera, A.; Cagossi, K.; Cavanna, L.; Ciccarese, M.; Cinieri, S. et al. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. Breast 2019, 48, 7–16.
Crossref Google Scholar
9

Yuan, Y. L.; Cai, T. G.; Xia, X.; Zhang, R. H.; Chiba, P.; Cai, Y. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer. Drug Deliv. 2016, 23, 3350–3357.
Crossref Google Scholar
10

Li, Y. L.; Gao, X. N.; Yu, Z. Z.; Liu, B.; Pan, W.; Li, N.; Tang, B. Reversing multidrug resistance by multiplexed gene silencing for enhanced breast cancer chemotherapy. ACS Appl. Mater. Interfaces 2018, 10, 15461–15466.
Crossref Google Scholar
11

Doyle, L. A.; Yang, W. D.; Abruzzo, L. V.; Krogmann, T.; Gao, Y. M.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665–15670.
Crossref Google Scholar
12

Chen, Z. L.; Shi, T. L.; Zhang, L.; Zhu, P. L.; Deng, M. Y.; Huang, C.; Hu, T. T.; Jiang, L.; Li, J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016, 370, 153–164.
Crossref Google Scholar
13

Shi, X. L.; Dou, Y. H.; Zhou, K. R.; Huo, J. L.; Yang, T. J.; Qin, T. T.; Liu, W. H.; Wang, S. Q.; Yang, D. X.; Chang, L. M. et al. Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line. Biomed. Pharmacother. 2017, 90, 897–905.
Crossref Google Scholar
14

Clarke, R.; Leonessa, F.; Trock, B. Multidrug resistance/P-glycoprotein and breast cancer: Review and meta-analysis. Semin. Oncol. 2005, 32, 9–15.
Crossref Google Scholar
15

Risnayanti, C.; Jang, Y. S.; Lee, J. J.; Ahn, H. J. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Sci. Rep. 2018, 8, 7498.
Crossref Google Scholar
16

Wu, Y.; Zhang, Y.; Zhang, W.; Sun, C. L.; Wu, J. Z.; Tang, J. H. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Colloids Surf. B Biointerfaces 2016, 138, 60–69.
Crossref Google Scholar
17

Mello, C. C.; Conte, D. Jr. Revealing the world of RNA interference. Nature 2004, 431, 338–342.
Crossref Google Scholar
18

Han, H. Y. RNA interference to knock down gene expression. Methods Mol. Biol. 2018, 1706, 293–302.
Crossref Google Scholar
19

Liu, H. M.; Wang, H.; Yang, W. J.; Cheng, Y. Y. Disulfide cross-linked low generation dendrimers with high gene transfection efficacy, low cytotoxicity, and low cost. J. Am. Chem. Soc. 2012, 134, 17680–17687.
Crossref Google Scholar
20

Shi, Y.; Lammers, T. Combining nanomedicine and immunotherapy. Acc. Chem. Res. 2019, 52, 1543–1554.
Crossref Google Scholar
21

Shen, W. W.; Wang, Q. W.; Shen, Y.; Gao, X.; Li, L.; Yan, Y.; Wang, H.; Cheng, Y. Y. Green tea catechin dramatically promotes RNAi mediated by low-molecular-weight polymers. ACS Cent. Sci. 2018, 4, 1326–1333.
Crossref Google Scholar
22

Yang, J. P.; Zhang, Q.; Chang, H.; Cheng, Y. Y. Surface-engineered dendrimers in gene delivery. Chem. Rev. 2015, 115, 5274–5300.
Crossref Google Scholar
23

Wang, H.; Huang, Q.; Chang, H.; Xiao, J. R.; Cheng, Y. Y. Stimuli-responsive dendrimers in drug delivery. Biomater. Sci. 2016, 4, 375–390.
Crossref Google Scholar
24

Lv, J.; Fan, Q. Q.; Wang, H.; Cheng, Y. Y. Polymers for cytosolic protein delivery. Biomaterials 2019, 218, 119358.
Crossref Google Scholar
25

Wang, M. M.; Liu, H. M.; Li, L.; Cheng, Y. Y. A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios. Nat. Commun. 2014, 5, 3053.
Crossref Google Scholar
26

Liu, H. M.; Wang, Y.; Wang, M. M.; Xiao, J. R.; Cheng, Y. Y. Fluorinated poly(propylenimine) dendrimers as gene vectors. Biomaterials 2014, 35, 5407–5413.
Crossref Google Scholar
27

Shi, C.; He, Y.; Feng, X. B.; Fu, D. H. ε-Polylysine and next-generation dendrigraft poly-L-lysine: Chemistry, activity, and applications in biopharmaceuticals. J. Biomater. Sci. Polym. Ed. 2015, 26, 1343–1356.
Crossref Google Scholar
28

Kim, S. W. Polylysine copolymers for gene delivery. Cold Spring Harb Protoc. 2012, 2012, 433–438.
Crossref Google Scholar
29

Chen, H. C.; Tian, J. W.; Liu, D. Y.; He, W. J.; Guo, Z. J. Dual aptamer modified dendrigraft poly-L-lysine nanoparticles for overcoming multi-drug resistance through mitochondrial targeting. J. Mater. Chem. B 2017, 5, 972–979.
Crossref Google Scholar
30

Kodama, Y.; Kuramoto, H.; Mieda, Y.; Muro, T.; Nakagawa, H.; Kurosaki, T.; Sakaguchi, M.; Nakamura, T.; Kitahara, T.; Sasaki, H. Application of biodegradable dendrigraft poly-L-lysine to a small interfering RNA delivery system. J. Drug Target. 2017, 25, 49–57.
Crossref Google Scholar
31

Kodama, Y.; Nakamura, T.; Kurosaki, T.; Egashira, K.; Mine, T.; Nakagawa, H.; Muro, T.; Kitahara, T.; Higuchi, N.; Sasaki, H. Biodegradable nanoparticles composed of dendrigraft poly-L-lysine for gene delivery. Eur. J. Pharm. Biopharm. 2014, 87, 472–479.
Crossref Google Scholar
32

Liu, Y.; Li, J. F.; Shao, K.; Huang, R. Q.; Ye, L. Y.; Lou, J. N.; Jiang, C. A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials 2010, 31, 5246–5257.
Crossref Google Scholar
33

Cottet, H.; Martin, M.; Papillaud, A.; Souaïd, E.; Collet, H.; Commeyras, A. Determination of dendrigraft poly-L-lysine diffusion coefficients by taylor dispersion analysis. Biomacromolecules 2007, 8, 3235–3243.
Crossref Google Scholar
34

Ryu, J. H.; Lee, G. J.; Shih, Y. R. V.; Kim, T. I.; Varghese, S. Phenylboronic acid-polymers for biomedical applications. Curr. Med. Chem. 2019, 26, 6797–6816.
Crossref Google Scholar
35

Winblade, N. D.; Nikolic, I. D.; Hoffman, A. S.; Hubbell, J. A. Blocking adhesion to cell and tissue surfaces by the chemisorption of a poly-L-lysine-graft-(poly(ethylene glycol); phenylboronic acid) copolymer. Biomacromolecules 2000, 1, 523–533.
Crossref Google Scholar
36

Peng, H. F.; Ning, X. Y.; Wei, G.; Wang, S. P.; Dai, G. L.; Ju, A. Q. The preparations of novel cellulose/phenylboronic acid composite intelligent bio-hydrogel and its glucose, pH-responsive behaviors. Carbohydr. Polym. 2018, 195, 349–355.
Crossref Google Scholar
37

Ye, L.; Liu, H. M.; Fei, X.; Ma, D.; He, X. Z.; Tang, Q. Y.; Zhao, X.; Zou, H. B.; Chen, X. J.; Kong, X. M. et al. Enhanced endosomal escape of dendrigraft poly-L-lysine polymers for the efficient gene therapy of breast cancer. Nano Res. 2021, 15, 1135–1144.
Crossref Google Scholar
38

Liu, C. Y.; Shao, N. M.; Wang, Y. T.; Cheng, Y. Y. Clustering small dendrimers into nanoaggregates for efficient DNA and siRNA delivery with minimal toxicity. Adv. Healthc. Mater. 2016, 5, 584–592.
Crossref Google Scholar
39

Liu, H. M.; Chang, H.; Lv, J.; Jiang, C.; Li, Z. X.; Wang, F.; Wang, H.; Wang, M. M.; Liu, C. Y.; Wang, X. Y. et al. Screening of efficient siRNA carriers in a library of surface-engineered dendrimers. Sci. Rep. 2016, 6, 25069.
Crossref Google Scholar
40

Liu, C. Y.; Wan, T.; Wang, H.; Zhang, S.; Ping, Y.; Cheng, Y. Y. A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci. Adv. 2019, 5, eaaw8922.
Crossref Google Scholar
41

Abnous, K.; Danesh, N. M.; Ramezani, M.; Alibolandi, M.; Bahreyni, A.; Lavaee, P.; Moosavian, S. A.; Taghdisi, S. M. A smart ATP-responsive chemotherapy drug-free delivery system using a DNA nanostructure for synergistic treatment of breast cancer in vitro and in vivo. J. Drug Target. 2020, 28, 852–859.
Crossref Google Scholar
42

Ma, D.; Liu, H. M.; Zhao, P. P.; Ye, L.; Zou, H. B.; Zhao, X.; Dai, H. L.; Kong, X. M.; Liu, P. F. Programing assembling/releasing multifunctional miRNA nanomedicine to treat prostate cancer. ACS Appl. Mater. Interfaces 2020, 12, 9032–9040.
Crossref Google Scholar
43

Friedl, P.; Alexander, S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011, 147, 992–1009.
Crossref Google Scholar
44

Paul, C. D.; Mistriotis, P.; Konstantopoulos, K. Cancer cell motility: Lessons from migration in confined spaces. Nat. Rev. Cancer 2017, 17, 131–140.
Crossref Google Scholar
45

Mattheolabakis, G.; Milane, L.; Singh, A.; Amiji, M. M. Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine. J. Drug Target. 2015, 23, 605–618.
Crossref Google Scholar
Nano Research
Volume 15 Issue 7,
July 2022
Pages 6306-6314
DOI: 10.1007/s12274-022-4254-1
Cite this article:
Liu H, Ma D, Chen J, et al. A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer. Nano Research, 2022, 15(7): 6306-6314. https://doi.org/10.1007/s12274-022-4254-1
Topics:
Targeted drug delivery

1080

Views

16

Crossref

16

Web of Science

17

Scopus

0

CSCD

Altmetrics
Received: 06 December 2021
Revised: 17 February 2022
Accepted: 20 February 2022
Published: 18 April 2022
© Tsinghua University Press 2022
Return